"A marketing collaboration with InterCure complements our existing product offering in the hypertension marketplace within the United Kingdom," said Steve MacAleese, General Manager, Omron Healthcare (UK). "We understand the value of not only offering a modality to diagnose the issue but to also provide an innovative treatment option for hypertension patients."
RESPeRATE(R) is FDA-cleared for over-the-counter sale and is the only medical device on the market clinically proven to lower blood pressure through paced breathing therapy. The device uses the body's natural tendency to follow external rhythms, interactively guiding the user to effortlessly reduce their breathing rate to a "therapeutic zone" of less than 10 breaths per minute. The breathing exercises with RESPeRATE relax the constricted muscles surrounding the small blood vessels, allowing the blood to flow more freely and yielding a significant and lasting reduction of blood pressure within weeks.
About InterCure, Ltd.
InterCure, a medical device company, publicly traded on the Tel Aviv
Stock Exchange (TASE: INCR) has become a leader in the growing Personal
Therapeutic Device category. Its broadly patented "device-guided breathing"
technology platform enables a systematic reduction in sympathetic outflow
of the autonomic nervous system. InterCure is successfully selling the
world's first hypertension treatment device, RESPeRATE(R), with more than
75,000 units sold. With multiple published clinical studies, regulatory
|SOURCE InterCure, Ltd.|
Copyright©2007 PR Newswire.